<DOC>
	<DOCNO>NCT00213018</DOCNO>
	<brief_summary>The primary aim study assess safety acceptability Carraguard ™ ( PC-515 ) apply vaginally least three time weekly 6-12 month . Secondary aim gather preliminary data Carraguard ’ effectiveness prevent male-to-female transmission HIV . The hypothesis Carraguard would cause little significant irritation , include lesion ; woman would find Carraguard acceptable . The study power determine effectiveness , base safety , acceptability feasibility parameter , outcome Phase 2 trial would enable decision whether proceed Phase 3 efficacy trial .</brief_summary>
	<brief_title>Safety , Acceptability Preliminary Effectiveness Carraguard™ ( PC-515 ) Preventing HIV/STI Transmission</brief_title>
	<detailed_description>Carraguard™ ( PC-515 ) , Population Council ’ lead candidate microbicide , test triple-masked , randomize , placebo-controlled trial field two site South Africa . The primary aim study assess Carraguard ’ safety ( toxicity ) – include sign irritation , itch burning ; change vaginal flora ; incidence abnormal external genital , vaginal , cervical finding – apply vaginally duration 6-12 month , evaluate several dimension acceptability Carraguard placebo product . Secondary aim investigate whether study participant use Carraguard low rate HIV seroconversion sexually transmit infection ( include C. trachomatis , N. gonorrhoeae , T. vaginalis , T. pallidum ) placebo ( methyl cellulose gel ) . In addition , begin , trial first explore feasibility large-scale microbicides test non-sex worker population . Last , trial gauge woman ’ reaction use non-contraceptive product ( vitro test show Carraguard contraceptive effect ) , well potential use-dynamics community dry agent traditional vaginal product use high frequency .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Syphilis</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Trichomonas Infections</mesh_term>
	<mesh_term>Trichomonas Vaginitis</mesh_term>
	<criteria>In good health determine medical history , physical examination result laboratory screening test RTIs Aged 18 year old Resident area least one year planning stay least 12 month HIVseronegative screen Willing able comply study protocol ( include test HIV , learn result , undergo clinical evaluation ) , , Able give inform consent Pregnant desire become pregnant trial Delivered abort pregnancy within six week prior screen History surgery external genitalia , vagina cervix six week prior screen Recent history nonmenstrual vaginal bleeding intercourse Clinically detectable genital abnormality ( include presence wart , structural congenital abnormality ) Clinical suspicion RTI ( define presence genital ulcer visible naked eye , abnormal vaginal discharge purulent cervicitis , untreated positive STI test result ) Abnormal Pap smear History sensitivity/allergy latex Participating another trial vaginal product Reported injection recreational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>microbicides</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>sexually transmit infection</keyword>
	<keyword>female-initiated protection</keyword>
	<keyword>carrageenan</keyword>
	<keyword>expand safety trial</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV</keyword>
</DOC>